finanzen.net
23.08.2019 20:21
Bewerten
(0)

Bionaze Probiotic awarded Federal Trademark

BOCA RATON, Fla., Aug. 23, 2019 /PRNewswire/ -- Specifically designed for ear, nose, and throat (ENT) care, the Bionaze probiotic supplement was awarded a U.S. Federal Trademark #5836379.   "We are very pleased that to receive the trademark for Bionaze as this will further enhance the value of our marketing strategy for this amazing new probiotic formula" says Bionaze's CEO Steve Williams.

The Bionaze product next to it's box. Bionaze is an all natural probiotic consisting of two clinically studied and patented probiotic bacteria strains. Studies have shown them to be effective in reducing the negative effects of chronic ear, nose, throat and sinus issues.

Bionaze is formulated with BLIS K12 and BL-04, both cutting edge probiotic strains clinically proven to prevent and reduce bacteria from taking hold.  Bionaze acts as a probiotic force field targeting chronic ENT and mouth issues thus preventing harmful bacterial growth. 

BLIS K12 is a relatively new probiotic strain with proven potential. Its main health benefit is getting rid of streptococcus pyogene - a harmful bacteria that causes tonsilitis, scarlet fever, and similar infections. BLIS K12 is also the strain of good bacteria responsible for infants "baby breath" and provides users long lasting breath benefit.

Bionaze works by attaching to your oral cavity and crowding out the bad bacteria inside. That's why it's ideal for getting rid of halitosis, gum disease or dry throat and using prior to, during and after being exposed to large groups of people such as while traveling or at sporting events.

In Milan, a study has confirmed the effectiveness of Bionaze's BLIS K12 in preventing streptococcal pharyngotonsilitis in children. The American Society for Microbiology also found that it helps prevent severe candidiasis.

Meanwhile, several studies have proven that the BL-04 contained in Bionaze is very effective in boosting immunity and preventing Strep Throat. In Australia, a trial was conducted to determine what probiotic strain best promotes immune functions. Participants who were given BL-04 have shown a 27% lower incidence of upper respiratory infections after 5 months. 

Recent clinical evidence shows that it also helps alleviate rhinovirus and hay fever in both adults and children. 

For those struggling with nasal allergies, this one two punch blend of probiotic strains each has proven to improve sinus health too. It does this by maintaining a healthy balance of bacteria in the upper respiratory tract. This, in turn, improves our body's tolerance to allergens.

Bionaze helps improve breathing, eliminates post-nasal drip and helps reduce phlegm by promoting proper drainage.

Williams started further,  "We know that for probiotic bacteria must reach your body alive. The two particular strains contained in Bionaze need time to attach in order to propagate in your oral cavities. Bionaze is formulated to taste great so we are very confident in the overall market acceptability and prospects for long term use."

"The slow dissolving lozenge exposes the bacteria to your oral surfaces for an extended period. This lets them to more effectively colonize your mouth and upper respiratory area. The longer it stays there, the faster you will feel its effects."

For more information about Bionaze visit www.Bionaze.com. Contact Info@Bionaze.com or call 800.931.1822.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bionaze-probiotic-awarded-federal-trademark-300906469.html

SOURCE Bionaze

Werbung
Werbung
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht kaum verändert ins Wochenende -- US-Börsen schließen im Minus -- CoBa will Stellen streichen -- Hoffnung auf Bewegung im Brexit-Streit -- K+S, Thomas Cook, Roche, HHLA im Fokus

Deutz kappt Gewinnprognose. Trump sieht Fortschritte bei Handelsgesprächen mit China. OSRAM-Aufsichtsratschef verkauft Aktien ebenfalls nicht an ams. Capital Group stockt E.ON-Anteile auf über 10 Prozent auf. TRATON-Beteiligung Navistar erwartet höhere Marge. Amazon startet Klimainitiative - 100.000 Elektro-Lieferwagen bestellt.

Die 5 beliebtesten Top-Rankings

Apple nicht mehr Platz 1
Das sind die wertvollsten Unternehmen der Welt 2019
Die wertvollsten Fußballvereine der Welt 2019
Welcher Club ist am wertvollsten?
Die 12 toten Topverdiener 2019
Diese Legenden sind die bestbezahlten Toten der Welt
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
mehr Top Rankings

Umfrage

Wo sehen Sie den DAX Ende 2019?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Wirecard AG747206
Deutsche Bank AG514000
Microsoft Corp.870747
CommerzbankCBK100
Daimler AG710000
Apple Inc.865985
NEL ASAA0B733
Amazon906866
Scout24 AGA12DM8
Infineon AG623100
Allianz840400
Ballard Power Inc.A0RENB
BASFBASF11
E.ON SEENAG99
Volkswagen (VW) AG Vz.766403